The Quality Use of Medicines: Serving Health and Economic Objectives?*

54 635 99 3 586 document 99 wp21_2003_sheehan.PDF application/pdf 88498 2011-09-09 10:19:45 https://vuir.vu.edu.au/54/1/wp21_2003_sheehan.PDF 54 1 application/pdf text en public

wp21_2003_sheehan.PDF

59754 2 2392231 document 59754 lightbox.jpg image/png 390ebda155f441da2fee0bdbb6d587bd MD5 56034 2020-08-13 01:00:36 https://vuir.vu.edu.au/54/3/lightbox.jpg 54 3 3 image/png other Thumbnails conversion from text to thumbnail_lightbox en staffonly

lightbox.jpg

preview.jpg

medium.jpg

small.jpg

http://eprints.org/relation/isVersionOf https://vuir.vu.edu.au/id/dark_document/59747 http://eprints.org/relation/isVolatileVersionOf https://vuir.vu.edu.au/id/dark_document/59747 http://eprints.org/relation/issmallThumbnailVersionOf https://vuir.vu.edu.au/id/dark_document/59747 archive 1 disk0/00/00/00/54 2005-10-12 2021-08-27 07:38:28 2008-08-19 18:49:55 monograph show Sheehan Peter Sheehan, Peter The Quality Use of Medicines: Serving Health and Economic Objectives?* pub 340000 cses medicines; pharmaceutical industry; australia The purpose of this paper is to provide a perspective on the issues to be discussed at the National Medicines Policy Partnerships Workshop, into, that discussion. A major theme of the paper is that there is an urgent need, in the interests of better health outcomes for the Australian people, to transcend the current environment of crisis and conflict linked to cost containment in medicines policy. One key to this is a real focus on the quality use of medicines (QUM) ensuring that all Australians get all of those cost effective medicines, and only those medicines, necessary for the best available health outcomes. 1996 published Victoria University CSES Working Paper No. 21 59747 2 2392221 dark_document 59747 Sheehan Peter.pdf application/pdf cbc314131c2872212f9758219ad384e9 MD5 103434 2020-08-13 00:59:22 54 2 2 application/pdf text Submission & Permission Form en staffonly

Sheehan Peter.pdf

other public working_paper Melbourne, Australia 20 Victoria University Centre for Strategic Economic Studies Australian Institute of Health and Welfare (AIHW) 2002,Health Expenditure in Australia 2001, Canberra. Australian Institute of Health and Welfare (AIHW) 2003, Health Expenditure in Australia 2002, Canberra. Catalan, V. S. and LeLorier, J. 2000,Predictors of Long-term Persistence on Statins in a Subsidised Clinical Population, Value in Health , vol. 3, pp. 417-426. Commonwealth of Australia 2002, Intergenerational Report 2002-03, Budget Paper no. 5, Canberra. Corbett, J. 2003, Because it Matters, Big Time, paper presented paper presented at the conference.The Future of the Pharmaceutical Benefits Scheme: Sustaining and Improving Australians Access to Quality Medicines, PBS, Sydney, 11-12 September.Datamonitor 2002,The New Generation Blockbusters, May, 6 & 26. George, B., Harris, A. and Mitchell, A. 1998,Reimbursement Decisions and the Implied Value of Life: Cost effectiveness analysis and decisions to reimburse pharmaceuticals in Australia 1993,in Harris, A. (ed), Economics and Health: Proceedings of the 19th Australian Conference of Health Economics, University of New South Wales, Sydney, pp. 1-17. Houghton, J.W. 2003, Australian ICT Industries Update 2003, sponsored by the Australian Computing Society, Centre for Strategic Economic Studies, Victoria University, Melbourne. IBM Global Services (IBMGS) 2002, Pharma 2010: The Threshold of Innovation, available at http://www-1.ibm.com/services/strategy/e_strategy/pharma_2010.html Lazarou, J., Pomeranz, B. et al. 1998,Incidence of adverse drug reactions in hospitalised patients: A meta-analysis of prospective,JAMA, vol. 279, no. 15, pp. 1200-1205. Lichtenberg, F. 1996,Do (more and better) drugs keep people out of hospitals?, American Economic Review, vol.86, no. 2, pp. 384-389. Lichtenberg, F. 2003,The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease Level Data from 52 Countries, 1981-2001, NBER Working Paper no. 9754, NBER, Cambridge, Mass. Market Letter: The Authoritative Newsletter for the World Health Care Industry 1999, Noncompliance costs almost $100 billion pa, IMS World Publications, London, 21 June. McGavock, H. 1996, A Review of the Literature on Drug Adherence, Royal Pharmaceutical Society of Great Britain, London. Nordhaus, W. 1999,The Health of Nations: The Contribution of Improved Health Standards, paper presented at the conference,Economic Returns of Medical Research, Lasker/Funding first, at http://www.laskerfoundation.org/reports/reports.html Sweeny, K. 2003,Price and Quantity Trends in the Pharmaceutical Benefits Scheme,Pharmaceutical Industry Project Draft Working Paper, Centre for Strategic Economic Studies, Melbourne. Wanless, D. 2002, Securing our Future Health: Taking a Long-Term View, HM Treasury, London, available at http://www.hmtreasury. gov.uk/consultations_and_legislation/wanless/consult_wanless_interimrep.cfm FALSE